New hope for tough cancers: experimental drug targets advanced tumors
NCT ID NCT07218003
Summary
This early-stage study is testing a new drug called RNDO-564, both by itself and combined with an existing immunotherapy (pembrolizumab), in adults with advanced cancers that have stopped responding to standard treatments. The main goals are to find safe doses and see how the body processes the drug. Researchers will also check if the treatment helps shrink tumors in patients with specific cancers, including bladder, lung, cervical, and breast cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina Biooncology
Huntersville, North Carolina, 28078, United States
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
START Center for Cancer Research
San Antonio, Texas, 78229, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute, LLD
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.